FDA Approves Itovebi for Locally Advanced, Metastatic Breast Cancer
Approval is for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.